InsidersTradesSigma
Rafael Holdings, Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the Rafael Holdings, Inc. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Rafael Holdings, Inc. has logged 69 public disclosures. Market capitalisation: €67.1m. The latest transaction was filed on 30 May 2025 (X). Among the most active insiders: CONKLING WILLIAM. The full history is accessible without an account.
69
Insider Decl.
0
Thresholds
€14m
3 ops.
Buy Volume
€124,941
3 ops.
Sell Volume
24Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 20,811 of 25,821 companies
30.1
score / 100
Value12
Quality48
FCF yld-9.4%
Earn yld-41%
EV/EBITDA·
ROE-41%
Gross mgn76%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 30 May 2025
Declarations69 total
76,882 shares@ US$1.2827.3% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-25-079559:0
27,454 sharesClass B Common Stock, par value $.01 per shareSEC:0000950170-25-057934:0
2,378 shares@ US$1.931.3% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-25-044471:0
14,814 shares@ US$1.935.4% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-25-044469:0
60,000 shares@ US$1.95423.5% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-25-005759:0
50,000 shares@ US$1.954100.0% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-25-005760:0
50,000 shares@ US$1.95430.1% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-25-005761:0
11,475 shares@ US$1.82100.0% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-25-003426:0
27,541 shares@ US$1.8223.3% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-25-003427:0
27,541 shares@ US$1.8222.8% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-25-003428:0
2,002 shares@ US$1.8351.1% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-24-139520:0
12,807 shares@ US$1.8354.7% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-24-139519:0
3,331 shares@ US$1.841.8% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-24-118363:0
3,431 shares@ US$1.841.2% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-24-118362:0
2,384 shares@ US$1.7251.2% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-24-108969:0
12,696 shares@ US$1.7254.0% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-24-108970:0
563,538 shares0Class B Common Stock, par value $.01 per shareSEC:0000950170-24-086819:0
563,538 shares0Class B Common Stock, par value $.01 per shareSEC:0000950170-24-078874:0
2,296 shares@ US$1.4551.0% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-24-077205:0
13,295 shares@ US$1.4553.7% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-24-077206:0
159,016 shares0Class B Common Stock, par value $.01 per shareSEC:0000950170-24-074317:0
348,259 shares0Class B Common Stock, par value $.01 per shareSEC:0000950170-24-042512:0
15,473 shares@ US$1.7055.0% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-24-035671:0
2,300 shares@ US$1.7051.1% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-24-035670:0
348,259 shares0Class B Common Stock, par value $.01 per shareSEC:0000950170-24-009772:0
25 of 69 declarations
About Rafael Holdings, Inc.
Rafael Holdings, Inc. (NYSE: RFL) is a United States-listed company trading on the NYSE/NASDAQ market, with a business profile that sits squarely in healthcare and biotech. Headquartered in Newark, New Jersey, the company has evolved from a more asset-holding structure into a development-focused biopharmaceutical platform centered on novel therapeutics, especially oncology and rare-disease opportunities. Its corporate base in Newark anchors the group in the northeastern United States. ([rafaelholdings.com](https://rafaelholdings.com/?utm_source=openai)) The company’s operating model is built around a portfolio of controlled and majority-owned healthcare ventures. In its latest annual report, Rafael Holdings describes itself as a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies developing pharmaceuticals and medical devices. Its lead candidate is Trappsol® Cyclo™, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare, fatal, progressive genetic disorder. Rafael also holds interests in LipoMedix Pharmaceuticals, Barer Institute, and Cornerstone Pharmaceuticals, and it has recently brought Cyclo Therapeutics into its consolidated portfolio. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1713863/000121390025103549/ea0262395-10k_rafael.htm?utm_source=openai)) From a competitive standpoint, Rafael is best viewed as a small-cap biotech company whose valuation is driven less by current commercial revenues and more by clinical execution, intellectual property, and capital-market access. Its competitive position depends on advancing specialized programs through development milestones, generating meaningful trial data, and maintaining flexibility to support portfolio companies. This is a high-risk, high-upside profile typical of development-stage biotech issuers, where clinical readouts and regulatory progress can materially re-rate the stock. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1713863/000121390025103549/ea0262395-10k_rafael.htm?utm_source=openai)) Recent corporate updates have centered on fiscal 2025 results for the year ended July 31, 2025, where the company reported a smaller net loss than in the prior year, alongside higher R&D spending tied to new consolidated activities. Management also highlighted continued progress on Trappsol® Cyclo™ and the broader transition toward a more integrated biopharmaceutical enterprise. For French-speaking investors, Rafael Holdings should be monitored as a speculative U.S. healthcare name on the NYSE, with key catalysts coming from clinical updates, SEC Form 4 insider filings, financing actions, and portfolio-level transactions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1713863/000121390025103509/ea026292601ex99-1_rafael.htm?utm_source=openai))
